Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects

Inclusion Criteria:

- No current or prior anti-HIV treatment, including antiretroviral medications received
for prevention (preexposure prophylaxis [PrEP]), or postexposure prophylaxis (PEP)
within 12 weeks of screening

- Must be between 18 and 65 years of age, inclusive on the date of the screening visit

- Plasma HIV-1 RNA ≥ 10,000 copies/mL but ≤ 400,000 copies/mL at screening

- CD4+ cell count > 200 cells/mm^3

Exclusion Criteria:

- Anticipated to start HIV-1 therapy during the study period

- Active participation in another study of investigational or approved antiretroviral
agents

- A new AIDS-defining condition diagnosed within the 30 days prior to screening

- Subjects with positive hepatitis C antibody at screening

- Chronic hepatitis B virus (HBV) infection

- Active, serious infections (other than HIV-1 infection) requiring parenteral
antibiotic or antifungal therapy within 42 days prior to Day 1 (baseline)